Eupraxia Pharmaceuticals ... (EPRX)
3.29
0.12 (3.79%)
At close: Apr 17, 2025, 3:59 PM
3.79% (1D)
| Bid | 3.04 |
| Market Cap | 117.94M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.61M |
| EPS (ttm) | -0.76 |
| PE Ratio (ttm) | -4.33 |
| Forward PE | -5.28 |
| Analyst | Buy |
| Ask | 3.5 |
| Volume | 4,750 |
| Avg. Volume (20D) | 14,632 |
| Open | 3.22 |
| Previous Close | 3.17 |
| Day's Range | 3.22 - 3.29 |
| 52-Week Range | 2.20 - 4.48 |
| Beta | 1.54 |
About EPRX
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-1...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 33
Stock Exchange NASDAQ
Ticker Symbol EPRX
Website https://www.eupraxiapharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for EPRX stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 173.56% from the latest price.
Stock Forecasts1 month ago
+10.37%
Eupraxia Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
4 months ago
+10.43%
Eupraxia Pharmaceuticals shares are trading higher after the company unveiled new pharmacokinetic data from its Phase 2A eosinophilic esophagitis program.